Your browser doesn't support javascript.
loading
Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.
Rabasco Meneghetti, Asier; Zwanenburg, Alex; Linge, Annett; Lohaus, Fabian; Grosser, Marianne; Baretton, Gustavo B; Kalinauskaite, Goda; Tinhofer, Ingeborg; Guberina, Maja; Stuschke, Martin; Balermpas, Panagiotis; von der Grün, Jens; Ganswindt, Ute; Belka, Claus; Peeken, Jan C; Combs, Stephanie E; Böke, Simon; Zips, Daniel; Troost, Esther G C; Krause, Mechthild; Baumann, Michael; Löck, Steffen.
Affiliation
  • Rabasco Meneghetti A; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Zwanenburg A; Institute of Radiooncology-OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
  • Linge A; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Lohaus F; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Grosser M; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Baretton GB; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Kalinauskaite G; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tinhofer I; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Guberina M; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Stuschke M; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstraße 74, 01307, Dresden, Germany.
  • Balermpas P; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • von der Grün J; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Ganswindt U; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Belka C; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Peeken JC; German Cancer Consortium (DKTK), Partner Site Dresden, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Combs SE; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden -
  • Böke S; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Zips D; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Troost EGC; Tumour- and Normal Tissue Bank, University Cancer Centre (UCC), University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Krause M; German Cancer Consortium (DKTK) Partner Site Berlin, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Baumann M; Department of Radiooncology and Radiotherapy, Charité University Medicine Berlin, Berlin, Germany.
  • Löck S; German Cancer Consortium (DKTK) Partner Site Berlin, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sci Rep ; 12(1): 16755, 2022 10 06.
Article in En | MEDLINE | ID: mdl-36202941
ABSTRACT
Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) may benefit from personalised treatment, requiring biomarkers that characterize the tumour and predict treatment response. We integrate pre-treatment CT radiomics and whole-transcriptome data from a multicentre retrospective cohort of 206 patients with locally advanced HNSCC treated with primary radiochemotherapy to classify tumour molecular subtypes based on radiomics, develop surrogate radiomics signatures for gene-based signatures related to different biological tumour characteristics and evaluate the potential of combining radiomics features with full-transcriptome data for the prediction of loco-regional control (LRC). Using end-to-end machine-learning, we developed and validated a model to classify tumours of the atypical subtype (AUC [95% confidence interval] 0.69 [0.53-0.83]) based on CT imaging, observed that CT-based radiomics models have limited value as surrogates for six selected gene signatures (AUC < 0.60), and showed that combining a radiomics signature with a transcriptomics signature consisting of two metagenes representing the hedgehog pathway and E2F transcriptional targets improves the prognostic value for LRC compared to both individual sources (validation C-index [95% confidence interval], combined 0.63 [0.55-0.73] vs radiomics 0.60 [0.50-0.71] and transcriptomics 0.59 [0.49-0.69]). These results underline the potential of multi-omics analyses to generate reliable biomarkers for future application in personalized oncology.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hedgehog Proteins / Head and Neck Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hedgehog Proteins / Head and Neck Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article